about
Activation of the human nuclear xenobiotic receptor PXR by the reverse transcriptase-targeted anti-HIV drug PNU-142721Structural Maturation of HIV-1 Reverse Transcriptase-A Metamorphic Solution to Genomic InstabilityNovel approaches to inhibiting HIV-1 replication.Anti-HIV-1 therapeutics: from FDA-approved drugs to hypothetical future targetsIdentification of alternative binding sites for inhibitors of HIV-1 ribonuclease H through comparative analysis of virtual enrichment studiesIdentification and characterization of a novel HIV-1 nucleotide-competing reverse transcriptase inhibitor series.Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agentsInteraction of HIV-1 reverse transcriptase ribonuclease H with an acylhydrazone inhibitor.Structural basis of the allosteric inhibitor interaction on the HIV-1 reverse transcriptase RNase H domain.Unfolding the HIV-1 reverse transcriptase RNase H domain--how to lose a molecular tug-of-war.The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemicsInhibitors of HIV-1 Reverse Transcriptase-Associated Ribonuclease H Activity.Formation of a quaternary complex of HIV-1 reverse transcriptase with a nucleotide-competing inhibitor and its ATP enhancer.Mutations M184V and Y115F in HIV-1 reverse transcriptase discriminate against "nucleotide-competing reverse transcriptase inhibitors".Pronounced Inhibition Shift from HIV Reverse Transcriptase to Herpetic DNA Polymerases by Increasing the Flexibility of α-Carboxy Nucleoside Phosphonates.Potent activity of a nucleoside reverse transcriptase inhibitor, 4'-ethynyl-2-fluoro-2'-deoxyadenosine, against human immunodeficiency virus type 1 infection in a model using human peripheral blood mononuclear cell-transplanted NOD/SCID Janus kinaseMicrowave-assisted syntheses of nucleosides and their precursors.Candidate antibody-based therapeutics against HIV-1.In search of a treatment for HIV--current therapies and the role of non-nucleoside reverse transcriptase inhibitors (NNRTIs).Interactions of HIV-1 proteins as targets for developing anti-HIV-1 peptides.Synthesis and anti-HIV activity of 4-(naphthalen-1-yl)-1,2,5-thiadiazol-3-hydroxyl derivatives.Pharmacophore Identification, Molecular Docking, Virtual Screening, and In Silico ADME Studies of Non-Nucleoside Reverse Transcriptase Inhibitors.Synthesis and biological evaluation of 6-substituted 5-alkyl-2-(phenylaminocarbonylmethylthio)pyrimidin-4(3H)-ones as potent HIV-1 NNRTIs.Green Technique-Solvent Free Microwave Synthesis and Antimicrobial Evaluation of New Thiopyridine Arabinosides.3D-QSAR analysis of a series of S-DABO derivatives as anti-HIV agents by CoMFA and CoMSIA.Facile synthesis of the NNRTI microbicide MC-1220 and synthesis of its phosphoramidate prodrugs.Computational development of rubromycin-based lead compounds for HIV-1 reverse transcriptase inhibition.Allosteric mechanism of quinoline inhibitors for HIV RT-associated RNase with MD simulation and dynamics fluctuation network.High-Technology Therapy Using Biomolecules or Synthetic Compounds for HIV Inhibition
P2860
Q27671326-E38E8C71-274A-4B42-A56B-3AB5F14E71E7Q28074527-B544181B-111E-4A94-812D-D4B0131EE801Q33624690-64B202C9-29C4-4EA8-8378-A44C68AB31FDQ33819240-353B5FBC-F845-4096-BD00-9B90EA230EEEQ33945786-BE2DF001-A878-49AF-9428-FB122830D9D0Q34643481-599266BD-6DEB-42DB-8B35-552F2DAB8670Q35673318-D017BD88-0153-474B-A4E4-D291F71AEB9FQ35874082-DE6F376E-2139-4D0F-BFBA-3899D5759A69Q36300994-1EAD41CD-21BD-462C-8D7B-616A5EFEFA44Q36627970-41EC1577-E4AF-41B9-9910-9E6305864D97Q36749580-024051AB-7982-44FB-B848-5C81219A00A8Q36768814-8FD45242-ABAF-41EB-952B-C67511C88BFDQ36928993-0706628C-2B04-4A8C-8D9D-C060A4D758F9Q36949351-209FADF0-9DAA-45C9-B1D1-5C274D508E16Q36970906-9FC20135-8DF9-4CD5-A49B-E70AFEEE68B6Q37333100-2E49345B-EAB4-4C8E-A72D-E30DE67D1F16Q37855917-F9F5D6D7-407F-416D-878D-E13861C39C93Q37998496-6DA3CBCA-510C-4CC6-8155-F6C14A259847Q38012389-CE7B086D-88DB-4CB1-B202-E1A9777BE4F3Q38524164-8AA635BF-177B-43EE-8EF5-C665B6DF6B05Q39011137-1764A7F4-4760-4CB2-AB36-617FEA4DA5A5Q39540759-ECD244D8-DE2B-4CD4-89C7-92F2A80B97A9Q39591934-14F2A833-1D0A-4724-9A95-C8BF9B0F0425Q39830689-3682996F-2E03-451A-8D95-8FBECC62272EQ40566306-F093BF08-691F-44CA-83F9-965895A3D185Q41095817-EF6C6724-D258-44E4-96CA-F5D04D090DBAQ42739347-5B257728-F16F-4E54-967B-DCE813BAEC63Q47579834-C2F92ED6-D3B2-422B-8E3B-CBFD9E67A38FQ55652601-745F5A65-6020-4903-8DE4-657845E0E11F
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Novel HIV-1 reverse transcriptase inhibitors.
@ast
Novel HIV-1 reverse transcriptase inhibitors.
@en
Novel HIV-1 reverse transcriptase inhibitors.
@nl
type
label
Novel HIV-1 reverse transcriptase inhibitors.
@ast
Novel HIV-1 reverse transcriptase inhibitors.
@en
Novel HIV-1 reverse transcriptase inhibitors.
@nl
prefLabel
Novel HIV-1 reverse transcriptase inhibitors.
@ast
Novel HIV-1 reverse transcriptase inhibitors.
@en
Novel HIV-1 reverse transcriptase inhibitors.
@nl
P1433
P1476
Novel HIV-1 reverse transcriptase inhibitors
@en
P2093
Dirk Jochmans
P304
P356
10.1016/J.VIRUSRES.2008.01.003
P577
2008-03-04T00:00:00Z